Thalidomide has also been tested in AD patients, but no differences in BACE1, a genetic measure of AD severity, were observed and 14 out of 25 patients dropped out of the trial due to adverse drug effects (Decourt et al., 2017), preventing the trial from administering the necessary dose to see an efficacious response (NCT01094340). The gene discussed is BACE1; the disease is Alzheimer disease.